Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells

Blood

Volumn 120, Issue 5, 2012, Pages 1118-1129

  Zhang, Yue ^a,b   Yan, Xiaomei ^a   Sashida, Goro ^a   Zhao, Xinghui ^a   Rao, Yalan ^a   Goyama, Susumu ^a   Whitman, Susan P ^c   Zorko, Nicholas ^c   Bernot, Kelsie ^c   Conway, Rajeana M ^a   Witte, David ^a   Wang, Qian Fei ^d   Tenen, Daniel G ^e,f   Xiao, Zhijian ^b   Marcucci, Guido ^c   Mulloy, James C ^a   Grimes, H Leighton ^a   Caligiuri, Michael A ^c   Huang, Gang ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^c OHIO STATE UNIVERSITY   (United States)

^d Chinese Academy of Sciences   (China)

^e HARVARD STEM CELL INSTITUTE   (United States)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL RENEWAL; CLONAL EVOLUTION; CONTROLLED STUDY; GENE; GENE DUPLICATION; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LEUKEMOGENESIS; MACROPHAGE; MLL GENE; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PARTIAL TANDEM DUPLICATION; PHENOTYPE; PRIORITY JOURNAL; STRESS;

EID: 84864548794     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-412379     Document Type: Article

References (50)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059-1064. (Pubitemid 27517875)
2. Zhang Y, Rowley JD. Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair (Amst). 2006;5(9):1282-97. (Pubitemid 44291613)
3. Graubert T, Walter MJ. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program. 2011;2011:543-549.
4. Nikoloski G, van der Reijden BA, Jansen JH. Mutations in epigenetic regulators in myelodysplastic syndromes. Int J Hematol. 2012;95(1):8-16.
5. Dicker F, Haferlach C, Sundermann J, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia. 2010;24(8):1528-1532.
6. Flach J, Dicker F, Schnitger S, et al. An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. Leukemia. 2011;25(4):713-718.
7. Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117(8):2348-2357.
8. Quentin S, Cuccuini W, Ceccaldi R, et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood. 2011;117(15):e161-e170.
9. Aplan PD. Chromosomal translocations involving the MLL gene: molecular mechanisms. DNA Repair (Amst). 2006;5(9):1265-1272. (Pubitemid 44308465)
10. Tan J, Muntean AG, Hess JL. PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget. 2010;1(6):461-465.
11. Mangan JK, Speck NA. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog. 2011;16(1):77-91.
12. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10(5):1107- 1117. (Pubitemid 35453828)
13. Tenney K, Shilatifard A. A COMPASS in the voyage of defining the role of trithorax/MLL-containing complexes: linking leukemogensis to covalent modifications of chromatin. J Cell Biochem. 2005;95(3):429-436. (Pubitemid 41420173)
14. Caligiuri MA, Schichman SA, Strout MP, et al. Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res. 1994;54(2):370-373. (Pubitemid 24053170)
15. Schichman SA, Caligiuri MA, Strout MP, et al. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res. 1994;54(16):4277-4280. (Pubitemid 24273133)
16. Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56(6):1418-1425. (Pubitemid 26080988)
17. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37(3):237-251. (Pubitemid 36667562)
18. Shih LY, Liang DC, Fu JF, et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia. 2006;20(2):218-223.
19. Whitman SP, Caliguri MA, Maharry K, et al. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia [published online ahead of print February 7, 2012]. Leukemia. doi:10.1038/leu.
20. Martin ME, Milne TA, Bloyer S, et al. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell. 2003;4(3):197-207. (Pubitemid 37163834)
21. Whitman SP, Liu S, Vukosavljevic T, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood. 2005;106(1):345-352. (Pubitemid 40967211)
22. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104(12):3679-3687. (Pubitemid 39564445)
23. Dorrance AM, Liu S, Yuan W, et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest. 2006;116(10):2707-2716. (Pubitemid 44511634)
24. Dorrance AM, Liu S, Chong A, et al. The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. Blood. 2008;112(6):2508-2511.
25. Ema H, Takano H, Sudo K, Nakauchi H. In vitro self-renewal division of hematopoietic stem cells. J Exp Med. 2000;192(9):1281-1288.
26. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872-1885.
27. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764. (Pubitemid 46582031)
28. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.
29. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163.
30. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-510.
31. Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol. 2006;135(4):438-449. (Pubitemid 44583410)
32. Dobson CL, Warren AJ, Pannell R, et al. The Mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J. 1999;18:3564-3574. (Pubitemid 29308837)
33. Chen W, Kumar AR, Hudson WA, et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 2008;13(5):432-440. (Pubitemid 351609442)
34. Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell. 2007;1(3):324-337. (Pubitemid 47355322)
35. Mata M, Chiffoleau E, Adler SH, Gray T, Hancock W, Turka LA. Bcl-XL expression in stem cells facilitates engraftment and reduces the need for host conditioning during bone marrow transplantation. Am J Transplant. 2004;4(1):58-64. (Pubitemid 38155490)
36. Kustikova OS, Geiger H, Li Z, et al. Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood. 2007;109(5):1897-1907. (Pubitemid 46348185)
37. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of proversus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103(4):1075-1082. (Pubitemid 29012647)
38. Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, Zikos P, Orphanos V, Zoumbos NC. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia. 1999;13(10):1554-1563. (Pubitemid 29465618)
39. Kurotaki H, Tsushima Y, Nagia K, Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome- derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol. 2000;102(3):115-123. (Pubitemid 30058099)
40. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96(12):3932-3938.
41. Boudard D, Vasselon C, Berthéas MF, et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol. 2002;70(2):115-125.
42. Suarez L, Vidriales MB, Sanz G, et al. Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34- bone marrow cell compartments from patients with myelodysplastic syndromes. Leukemia. 2004;18(7):1311-1313. (Pubitemid 39023144)
43. Bar M, Stirewalt D, Pogosova-Agadjanyan E, et al. Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression. Transl Oncogenomics. 2008;3:137-149. (Pubitemid 351850778)
44. Hellstrom-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol. 2008;45(1):14-22.
45. Rigolin GM, Castoldi G. The role of rHuEpo in low-risk myelodysplastic syndrome patients. Leuk Lymphoma. 2005;46(6):823-831. (Pubitemid 40959671)
46. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116(17):3163-3170.
47. Kirito K, Watanabe T, Sawada K, Endo H, Ozawa K, Komatsu N. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem. 2002;277(10):8329-8337. (Pubitemid 34968293)
48. Moucadel V, Constantinescu SN. Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. J Biol Chem. 2005;280(14):13364-13373. (Pubitemid 40517223)
49. Ivanovic Z, Stosic-Grujicic S. The in vivo effect of recombinant human interleukin-1 receptor antagonist on spleen colony forming cells after radiation induced myelosuppression. Eur Cytokine Netw. 1995;6(3):177-180.
50. Huang G, et al. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood. 2011;118(25):6544-6552.